Compare AESI & IDYA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | AESI | IDYA |
|---|---|---|
| Founded | 2017 | 2015 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Metal Fabrications | Biotechnology: Pharmaceutical Preparations |
| Sector | Industrials | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 2.4B | 2.6B |
| IPO Year | 2023 | 2019 |
| Metric | AESI | IDYA |
|---|---|---|
| Price | $19.44 | $29.07 |
| Analyst Decision | Hold | Strong Buy |
| Analyst Count | 6 | 16 |
| Target Price | $13.17 | ★ $52.86 |
| AVG Volume (30 Days) | ★ 4.4M | 737.2K |
| Earning Date | 05-04-2026 | 05-06-2026 |
| Dividend Yield | ★ 2.91% | N/A |
| EPS Growth | N/A | ★ 61.90 |
| EPS | ★ N/A | N/A |
| Revenue | ★ $1,095,310,000.00 | $218,710,000.00 |
| Revenue This Year | $2.71 | N/A |
| Revenue Next Year | $17.78 | $201.05 |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | 3.73 | ★ 3024.43 |
| 52 Week Low | $7.64 | $19.26 |
| 52 Week High | $20.13 | $39.28 |
| Indicator | AESI | IDYA |
|---|---|---|
| Relative Strength Index (RSI) | 66.76 | 46.35 |
| Support Level | $10.76 | $27.66 |
| Resistance Level | $19.61 | $29.50 |
| Average True Range (ATR) | 0.96 | 1.06 |
| MACD | -0.13 | 0.22 |
| Stochastic Oscillator | 75.65 | 60.71 |
Atlas Energy Solutions Inc is a provider of proppant and logistics services to the oil and natural gas industry within the Permian Basin of West Texas and New Mexico, the active oil and natural gas basin in North America. Proppant is necessary to facilitate the recovery of hydrocarbons from oil and natural gas wells. One hundred percent of its sand reserves are located in Winkler and Ward Counties, Texas, within the Permian Basin, and its operations consist of proppant production and processing facilities, including two facilities near Kermit, Texas, and a third facility near Monahans, Texas.
IDEAYA Biosciences Inc is an oncology-focused precision medicine company committed to the discovery and development of targeted therapeutics for patient populations selected using molecular diagnostics. Its approach integrates small molecule drug discovery with extensive capabilities in identifying and validating translational biomarkers to develop targeted therapies for select patient populations that are likely to benefit from these targeted therapies. The company's clinical-stage product candidates include darovasertib (PKC), IDE397 (MAT2A), IDE849 (DLL3), IDE275 (Werner Helicase), IDE161 (PARG), and IDE705 (Pol Theta Helicase). In addition, it also working on other development candidates and has multiple earlier-stage preclinical programs.